OncoTherapy Science, Inc. (4564) Stock Price

OncoTherapy Science is a research and development-focused venture company founded in 2001 based on the research achievements of Professor Yusuke Nakamura, Professor Emeritus at the University of Tokyo. The company focuses on pharmaceutical research and development, large-scale cancer gene analysis testing, and cancer immunotherapy research and development.

Against the backdrop of advances in genomic research, the company is engaged in "genome drug discovery," which leverages genetic information. In particular, it is developing pharmaceuticals targeting genes associated with diseases such as cancer, diabetes, and hypertension. Through this approach, the company aims to realize effective treatments that eliminate the root causes of diseases, rather than relying on conventional symptomatic therapies.

OncoTherapy Science is also exploring new approaches in cancer treatment. It is developing molecular targeted therapies and immunotherapies as alternatives to conventional chemotherapy, with the goal of providing more effective treatments with fewer side effects. This is expected to extend survival periods for cancer patients and enable longer-term treatment.

The company is also focusing on cancer precision medicine-related business. Through cancer gene analysis, it aims to provide optimal treatment methods tailored to individual patients. In partnership with Theragen Bio Co., Ltd., the company established Cancer Precision Medicine, a subsidiary that conducts large-scale cancer gene analysis testing and cancer immunotherapy research and development.

OncoTherapy Science's pharmaceutical development is divided into three areas: small molecule drugs, peptide vaccines, and antibody drugs. Small molecule drugs target proteins derived from cancer-related genes, peptide vaccines use immune mechanisms to attack cancer cells, and antibody drugs are pharmaceuticals that react to specific proteins on the surface of cancer cells.

The company's business revenue consists of upfront contract payments, milestone payments, and royalties based on contracts with pharmaceutical companies. Since pharmaceutical development requires extended periods, revenue generation depends on the research and development progress of contract partners. This may result in significant fluctuations in business performance.

Oncotherapy Science focuses on developing cancer treatment drugs while advancing research in cancer genetic analysis and immunotherapy. The company aims to provide more effective treatments with fewer side effects, conducting integrated operations from basic research through drug discovery to clinical development.

The company's growth strategy centers on advancing cancer precision medicine. Specifically, it aims to provide optimal treatment for individual patients through genetic analysis of cancer cells. This approach seeks to maximize treatment effectiveness and improve patients' quality of life.

Oncotherapy Science conducts drug discovery research across three areas: small molecule drugs, peptide vaccines, and antibody therapeutics. These research efforts target cancer cells specifically, advancing the development of safer and more effective treatments.

The company's revenue model depends on partnerships with pharmaceutical companies, including upfront contract payments, milestone payments, and royalties. This approach aims to secure revenue according to research and development progress and achieve stable management.

Additionally, Oncotherapy Science pursues business expansion through developing new partnerships and strengthening relationships with existing partners. This strategy aims to bring cancer treatment drugs to market earlier and contribute to society.